Heilongjiang ZBD Pharmaceutical Co., Ltd.

Equities

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-06-13 pm EDT 5-day change 1st Jan Change
11.85 CNY -1.90% Intraday chart for Heilongjiang ZBD Pharmaceutical Co., Ltd. -2.23% -2.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets MT
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies MT
Heilongjiang ZBD Gets Approval for Traditional Medicine Product MT
Heilongjiang ZBD’s Anti-Pulmonary Fibrosis Drug Gets U.S. Patent MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. from Hulin Longpeng Investment Center. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.
More charts
HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603567 Stock
  4. News Heilongjiang ZBD Pharmaceutical Co., Ltd.
  5. ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets